Bavelloni, A. (2017) “PI3Kα-selective inhibitor alpelisib (BYL719), may be effective as anticancer agents in Rhabdomyosarcoma”, Italian Journal of Anatomy and Embryology, 122(1), p. 21. doi: 10.36253/ijae-1730.